SFO
DFTX

Stokes Family Office’s Definium Therapeutics DFTX Stock Holding History

Stokes Family Office’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,073
Closed -$111K – 258
2021
Q3 		$111K Hold
3,073
– – 0.02% 224
2021
Q2 		$160K Buy
+3,073
New +$161K 0.02% 211

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Stokes Family Office's DFTX Position: Q4 2021 in Review

Stokes Family Office sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 3,073 shares — an estimated $111K sold.

Stokes Family Office first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $160K in Q2 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

  • Stokes Family Office reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Stokes Family Office sold 3,073 Definium Therapeutics shares in Q4 2021, an estimated $111K.
  • Stokes Family Office first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
  • Stokes Family Office's Definium Therapeutics position peaked at $160K in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on Stokes Family Office's 13F filing for Q4 2021, filed 15 Feb 2022.